GlassScriptPhysician profile
Matthew R Swelstad
NPI 1215970926
$22,006.50
in general payments reported to CMS, 2019-2025
11 companies · $1,818 in 2025
The $1,818 reported for 2025 was more than what 82% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $124 · 2021: $133 · 2022: $115 · 2023: $334 · 2024: $760 · 2025: $1,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,912.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $18,774.26 | 2019-2022 | |
| Abbvie INC. | $2,383.43 | 2023-2025 | Botox, Natrelle Saline-Filled Breast Implants |
| Kls-Martin L.P. | $391.51 | 2020-2025 | |
| Integra Lifesciences Corporation | $159.19 | 2020-2025 | Integra, Surgimend, Integra Dermal Regeneration Template |
| Tei Biosciences INC | $103.28 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $63.58 | 2021-2023 | |
| Stryker Corporation | $43.40 | 2019 | |
| Davol INC. | $30.99 | 2021 | |
| Tela Bio, INC. | $25.02 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Regeneron Healthcare Solutions, INC. | $17.23 | 2025 | Libtayo |
| Olympus America INC. | $14.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Swelstad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.